It's a question many face when managing a chronic condition like asthma: how much will my medication cost? For AIRSUPRA®, the first and only FDA-approved inhaled anti-inflammatory reliever for asthma, understanding the financial aspect is crucial for consistent treatment. AstraZeneca, the company behind AIRSUPRA®, has introduced programs designed to make this important medication more accessible.
Starting June 1, 2024, AstraZeneca is offering a significant co-pay assistance program. Eligible patients can now pay no more than $35 per month for all their inhaled respiratory medicines, including AIRSUPRA®. This initiative aims to remove a common barrier to consistent care, ensuring that patients can access the relief they need without undue financial strain.
If you're wondering about your eligibility for this program, or if you have questions about how it works, reaching out directly is the best step. You can contact AstraZeneca's patient support line at +1 (800) 236-9933. They can guide you through the specifics and help determine if you qualify.
It's important to note that certain terms and conditions apply. For instance, individuals enrolled in federal government insurance programs may be excluded from this particular co-pay support. However, if you don't meet the criteria for the $35 co-pay program and are finding your medication unaffordable, AstraZeneca also offers the AZ&Me program, which might provide further assistance. Exploring these options can make a real difference in managing your asthma.
AIRSUPRA® itself is a significant development in asthma management. Approved by the FDA in January 2023, it's designed for adults with asthma to treat symptoms and inflammation simultaneously, helping to prevent asthma attacks. It combines a short-acting beta2-agonist (SABA) to open airways and an inhaled corticosteroid (ICS) to reduce inflammation. This dual action is a departure from traditional SABA-only relievers, which don't address the underlying inflammation. Studies like MANDALA have shown AIRSUPRA® to be more effective than albuterol alone in reducing the risk of severe asthma exacerbations for moderate to severe asthma patients, while the DENALI trial demonstrated improved lung function in mild to moderate asthma patients.
For those considering AIRSUPRA®, it's always recommended to discuss it with your healthcare provider to see if it's the right fit for your specific asthma management plan. They can also help you navigate the financial assistance programs available.
